Agenus Reports Long-Term Survival Data for BOT+BAL in Refractory MSS Metastatic Colorectal Cancer at SITC 2026

Agenus reported at the SITC 2026 meeting that more than 50% of patients with refractory microsatellite-stable metastatic colorectal cancer treated with botensilimab plus balstilimab (BOT+BAL) achieved long-term survival. The data, disclosed November 6, 2026, reflect ongoing clinical evaluation of the company’s lead immunotherapy combination; the report provided no financial results or stock-price impact.